5.07
-0.81 (-13.78%)
| Previous Close | 5.88 |
| Open | 5.35 |
| Volume | 5,970,643 |
| Avg. Volume (3M) | 3,010,663 |
| Market Cap | 166,294,608 |
| Price / Book | 0.900 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.14 |
| Total Debt/Equity (MRQ) | 19.91% |
| Current Ratio (MRQ) | 4.95 |
| Operating Cash Flow (TTM) | -82.77 M |
| Levered Free Cash Flow (TTM) | -46.26 M |
| Return on Assets (TTM) | -40.84% |
| Return on Equity (TTM) | -75.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | PepGen Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.27% |
| % Held by Institutions | 95.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ikarian Capital, Llc | 30 Jun 2025 | 150,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (Stifel, 136.69%) | Buy |
| 12.00 (HC Wainwright & Co., 136.69%) | Buy | |
| Median | 10.00 (97.24%) | |
| Low | 6.00 (Guggenheim, 18.34%) | Buy |
| Average | 9.50 (87.38%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 4.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 30 Sep 2025 | 8.00 (57.79%) | Buy | 5.07 |
| 25 Sep 2025 | 9.00 (77.51%) | Buy | 5.88 | |
| HC Wainwright & Co. | 25 Sep 2025 | 12.00 (136.69%) | Buy | 5.88 |
| Stifel | 25 Sep 2025 | 12.00 (136.69%) | Buy | 5.88 |
| Guggenheim | 24 Sep 2025 | 6.00 (18.34%) | Buy | 2.66 |
| 09 Sep 2025 | 6.00 (18.34%) | Buy | 1.48 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Sep 2025 | Announcement | PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares |
| 24 Sep 2025 | Announcement | PepGen Announces Pricing of $100 Million Public Offering |
| 24 Sep 2025 | Announcement | PepGen Announces Proposed Public Offering |
| 24 Sep 2025 | Announcement | PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients |
| 07 Aug 2025 | Announcement | PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |